Retatrutide vs Tirzepatide: Next-Generation Comparison for South Africa
As the peptide market evolves, South African researchers and health practitioners are comparing retatrutide (triple agonist) with tirzepatide (dual agonist) to understand which offers superior outcomes.
Key Differences
- Tirzepatide: Targets GIP and GLP-1 receptors. Average 20-25% weight loss.
- Retatrutide: Targets GIP, GLP-1, and glucagon receptors. Up to 24%+ in clinical trials.
The glucagon component of retatrutide adds a fat-burning dimension that tirzepatide doesn’t offer. However, tirzepatide has more extensive clinical data and a longer safety track record.
Both are available as research-grade products at Cronopharm. Compare them in our product catalogue.
Disclaimer: This article is for informational and research purposes only. It does not constitute medical advice or a recommendation for treatment. Statements regarding potential benefits are based on preliminary research and clinical studies. Individual results may vary. These products are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before making any decisions about your health.
